3rd Quarter - Report

TARPLIN STRATEGIES LLC for GENENTECH, INC.

Firm
Client
Income
$75,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program, structure of the Medicare prescription drug benefit. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid reimbursement, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescriptiondrug benefit. Public Law 112-144, the Food and Drug Administration Safety and Innovation Act - legislation related to reauthorization of user fees for prescription drug, medical device, and biologics approval. All aspects. General issues and congressional oversight related to FDA approval and CMS coverage decisions regarding Avastin and Lucentis S. 959 - Pharmaceutical Quality, Security, and Accountability Act - legislation regarding pharmacy compounding and track and trace proposals. H.R. 2186 - Valid Compounding Act H.R. 1919 - Safeguarding America's Pharmaceuticals Act of 2013, track and trace H.R. 3089 - the Compounding Clarity Act - pharmacy compounding and track and trace proposals. H.R. 3204 - the Drug Quality and Security Act - pharmacy compounding and track and trace proposals.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB)

Bills named: H.R. 3089 (113th), H.R. 1919 (113th), H.R. 3204 (113th), H.R. 2186 (113th), S. 959 (113th)

Health Issues HCR

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Office of Management & Budget (OMB)

Medicare/Medicaid MMM

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics. Meetings with Administration and congressional staff on coverage/payment issues related to cancer biotherapeutics, 340B program. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues.H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023; and S.Con.Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S. 388, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues. S.Con.Res. 8, establishing budget for 2014

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families

Contacted: HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 388 (113th), S.Con.Res. 8 (113th), H.Con.Res. 25 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.